In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biopharma In 2013: A Rising Tide

Executive Summary

Big launches, clinical success in key therapeutic areas like cancer immunotherapy, and renewed interest in biotech from a broad investor base floated the biopharma world through 2013’s average year for FDA approvals, the rocky rollout of the Affordable Care Act, and increasing concern about drug prices.

Advertisement

Related Content

2013’s Top Biopharma Dealmakers
2013’s Top Biopharma Dealmakers
2013: The Year In Diagnostics
Medication Adherence: A Positive Story You Are Not Hearing
Pharmacyclics/Janssen Offer Suite Of Patient Support Programs For Imbruvica
Merck’s “Beyond The Pill” Bet, Vree Health, Goes Commercial
Drug Spending Expected To Rise By $200 Bil. In 2022 Compared To Pre-ACA Levels
Biopharma M&A In An Era Of Elusive Growth, Capital Triage, and New Competitors
Roche Experimenting With New Pricing Models In Oncology

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV004122

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel